Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 14 Non-Muscle Invasive Bladder Neoplasms 10 Colorectal Neoplasms 7 Appendiceal Neoplasms 6 Anus Neoplasms 6 Peritoneal Neoplasms 5 Carcinoma, Transitional Cell 5 Stomach Neoplasms 2 Pseudomyxoma Peritonei 2 Ovarian Neoplasms 2 Uterine Neoplasms 1 Urothelial Carcinoma of the Bladder 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Urinary Bladder Diseases 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Pleural Neoplasms 1 Peritoneal Diseases 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Necrosis 1 Nasopharyngeal Carcinoma 1 Mediastinal Neoplasms 1 Male Urogenital Diseases 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Mitomycin × 1 year × Clear all

NCT06781879 2025-10-03

COBRA-NMIBC

Aarhus University Hospital

Phase 4 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡